Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Fresenius Medical Care AG & Co. KGaA
  6. Financials
    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
Delayed Xetra  -  11:35 2022-08-12 am EDT
36.65 EUR   -0.81%
08/08Credit Suisse Cuts Price Target on Fresenius Medical Care to EUR47 From EUR61, Citing 'Major Margin Pressure,' Keeps Neutral Rating
MT
08/08FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Receives a Buy rating from Berenberg
MD
08/05FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Credit Suisse sticks Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 19 67219 97416 74210 754--
Enterprise Value (EV)1 32 44731 27228 58022 29821 86821 274
P/E ratio 16,7x17,2x17,3x15,8x10,7x8,65x
Yield 1,82%1,96%2,36%3,00%3,45%3,94%
Capitalization / Revenue 1,13x1,12x0,95x0,56x0,54x0,51x
EV / Revenue 1,86x1,75x1,62x1,17x1,09x1,01x
EV / EBITDA 8,40x7,65x8,22x6,82x5,93x5,13x
Price to Book 1,67x1,78x1,32x0,83x0,79x0,74x
Nbr of stocks (in thousands) 298 249292 869292 994293 413--
Reference price (EUR) 66,068,257,136,736,736,7
Announcement Date 02/20/202002/23/202102/22/2022---
1 EUR in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 17 47717 85917 61919 08620 08121 076
EBITDA1 3 8634 0903 4763 2703 6904 148
Operating profit (EBIT)1 2 2702 3041 8521 5661 9592 322
Operating Margin 13,0%12,9%10,5%8,21%9,75%11,0%
Pre-Tax Profit (EBT)1 1 8411 9361 5721 2791 6721 982
Net income1 1 2001 1649697001 0271 274
Net margin 6,87%6,52%5,50%3,67%5,11%6,04%
EPS2 3,963,963,312,323,424,24
Dividend per Share2 1,201,341,351,101,261,44
Announcement Date 02/20/202002/23/202102/22/2022---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 4 4414 6474 5484 7574 7254 933
EBITDA1 907895767-811828
Operating profit (EBIT)1 505449348341395399
Operating Margin 11,4%9,67%7,65%7,17%8,36%8,10%
Pre-Tax Profit (EBT) 436382279---
Net income1 273229157147185163
Net margin 6,15%4,92%3,45%3,09%3,91%3,30%
EPS2 0,930,780,540,500,630,55
Dividend per Share ------
Announcement Date 11/02/202102/22/202205/04/202207/28/2022--
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 12 77511 29811 83811 54511 11510 520
Net Cash position1 ------
Leverage (Debt / EBITDA) 3,31x2,76x3,41x3,53x3,01x2,54x
Free Cash Flow1 1 4423 1971 6601 4291 6541 830
ROE (Net Profit / Equities) 11,5%11,7%7,37%6,42%8,10%9,35%
Shareholders' equity1 10 3949 92713 15910 90912 68113 626
ROA (Net Profit / Asset) 4,06%3,60%2,93%2,18%2,58%3,45%
Assets1 29 58932 30833 03832 15039 86636 886
Book Value Per Share2 39,538,343,344,346,649,6
Cash Flow per Share2 8,4814,48,506,818,289,35
Capex1 1 1251 0368291 1211 2051 267
Capex / Sales 6,44%5,80%4,71%5,88%6,00%6,01%
Announcement Date 02/20/202002/23/202102/22/2022---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Analysis
U.S. Supreme Court rules against DaVita over dialysis coverage
Key data
Capitalization (EUR) 10 753 602 905
Capitalization (USD) 11 025 943 715
Net sales (EUR) 17 618 685 000
Net sales (USD) 18 064 887 727
Number of employees 123 153
Sales / Employee (EUR) 143 063
Sales / Employee (USD) 146 687
Free-Float 67,9%
Free-Float capitalization (EUR) 7 304 747 004
Free-Float capitalization (USD) 7 489 743 673
Avg. Exchange 20 sessions (EUR) 40 533 319
Avg. Exchange 20 sessions (USD) 41 559 847
Average Daily Capital Traded 0,38%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA